Bedaquiline - Janssen Infectious Diseases BVBA

Drug Profile

Bedaquiline - Janssen Infectious Diseases BVBA

Alternative Names: AIDS-222089; Bedaquiline fumarate; R 403323; R-207910; Sirturo; TMC-207; TMC207 oral solution

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Developer Global Alliance for TB Drug Development; Janssen Infectious Diseases BVBA
  • Class Antituberculars; Dimethylamines; Naphthalenes; Quinolines; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 16 Nov 2017 Global Alliance for TB Drug Development plans a phase IIc trial for Tuberculosis (Combination therapy) in August 2018 (NCT03338621)
  • 25 Apr 2017 Preregistration for Tuberculosis (Combination therapy) in Japan (PO)
  • 13 Feb 2017 Adverse events and efficacy data from a phase I trial in Tuberculosis presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top